Logo do repositório
 
Publicação

HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola

2024-12Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorSebastião, Cruz S.
dc.contributor.authorAbecasis, Ana B.
dc.contributor.authorJandondo, Domingos
dc.contributor.authorSebastião, Joana M. K.
dc.contributor.authorVigário, João
dc.contributor.authorComandante, Felícia
dc.contributor.authorPingarilho, Marta
dc.contributor.authorPocongo, Bárbara
dc.contributor.authorCassinela, Edson
dc.contributor.authorGonçalves, Fátima
dc.contributor.authorGomes, Perpétua
dc.contributor.authorGiovanetti, Marta
dc.contributor.authorFrancisco, Ngiambudulu M.
dc.contributor.authorSacomboio, Euclides
dc.contributor.authorBrito, Miguel
dc.contributor.authorNeto de Vasconcelos, Jocelyne
dc.contributor.authorMorais, Joana
dc.contributor.authorPimentel, Victor
dc.contributor.institutionGlobal Health and Tropical Medicine (GHTM)
dc.contributor.institutionTB, HIV and opportunistic diseases and pathogens (THOP)
dc.contributor.institutionInstituto de Higiene e Medicina Tropical (IHMT)
dc.contributor.pblNature Publishing Group
dc.date.accessioned2024-09-30T22:30:37Z
dc.date.available2024-09-30T22:30:37Z
dc.date.issued2024-12
dc.descriptionFunding Information: We would like to thank all subjects who participated in this study and all staff of the National Blood Institute (Mr Alberto Sozinho, Ms Eunice Manico, and Ms Deodete Machado) and the research team of CISA/INIS for the data collection (Mr Pedro Vienga and Mr Agostinho Tchipeta) for the data collection, the laboratory technician (Ms. Anabela Mateus), and administrative staff members (Zinga David and Sara Isalino) for their supports. Funding Information: This research was funded by the Funda\u00E7\u00E3o Calouste Gulbenkian (FCG), under the ENVOLVE Ci\u00EAncia PALOP program that funded the HITOLA project (Number 250466), AREF (AREF-312-CRUZ-F-C0931), Science and Technology Development Project (PDCT) within the scope of the MUTHIVAO project (Number 36 MESCTI/PDCT/2022), FCT MARVEL (PTDC/SAU-PUB/4018/2021), FCT GHTM-UID/04413/2020 and LA-REAL-LA/P/0117/2020. Publisher Copyright: © The Author(s) 2024.
dc.description.abstractThe surveillance of drug resistance in the HIV-1 naïve population remains critical to optimizing the effectiveness of antiretroviral therapy (ART), mainly in the era of integrase strand transfer inhibitor (INSTI) regimens. Currently, there is no data regarding resistance to INSTI in Angola since Dolutegravir-DTG was included in the first-line ART regimen. Herein, we investigated the HIV-1 genetic diversity and pretreatment drug resistance (PDR) profile against nucleoside/tide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and INSTIs, using a next-generation sequencing (NGS) approach with MinION, established to track and survey DRMs in Angola. This was a cross-sectional study comprising 48 newly HIV-diagnosed patients from Luanda, Angola, screened between March 2022 and May 2023. PR, RT, and IN fragments were sequenced for drug resistance and molecular transmission cluster analysis. A total of 45 out of the 48 plasma samples were successfully sequenced. Of these, 10/45 (22.2%) presented PDR to PIs/NRTIs/NNRTIs. Major mutations for NRTIs (2.2%), NNRTIs (20%), PIs (2.2%), and accessory mutations against INSTIs (13.3%) were detected. No major mutations against INSTIs were detected. M41L (2%) and I85V (2%) mutations were detected for NRTI and PI, respectively. K103N (7%), Y181C (7%), and K101E (7%) mutations were frequently observed in NNRTI. The L74M (9%) accessory mutation was frequently observed in the INSTI class. HIV-1 pure subtypes C (33%), F1 (17%), G (15%), A1 (10%), H (6%), and D (4%), CRF01_AG (4%) were observed, while about 10% were recombinant strains. About 31% of detected HIV-1C sequences were in clusters, suggesting small-scale local transmission chains. No major mutations against integrase inhibitors were detected, supporting the continued use of INSTI in the country. Further studies assessing the HIV-1 epidemiology in the era of INSTI-based ART regimens are needed in Angola.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1435569
dc.identifier.doi10.1038/s41598-024-66905-1
dc.identifier.issn2045-2322
dc.identifier.otherPURE: 99692813
dc.identifier.otherPURE UUID: 0ca3352f-fcb1-431b-95c1-80e5b48cf886
dc.identifier.otherScopus: 85198142968
dc.identifier.otherWOS: 001270506400044
dc.identifier.otherPubMed: 38987263
dc.identifier.otherPubMedCentral: PMC11237101
dc.identifier.urihttp://hdl.handle.net/10362/172721
dc.identifier.urlhttps://www.scopus.com/pages/publications/85198142968
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAngola
dc.subjectDrug resistance mutations
dc.subjectGenetic diversity
dc.subjectHIV-1
dc.subjectINSTI
dc.subjectNGS
dc.subjectGeneral
dc.subjectSDG 3 - Good Health and Well-being
dc.titleHIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angolaen
dc.typejournal article
degois.publication.issue1
degois.publication.titleScientific Reports
degois.publication.volume14
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
HIV-1_diversity_and_pre-treatment_drug_resistance_in_the_era_of_integrase_inhibitor_among_newly_diagnosed_ART-na_ve_adult_patients_in_Luanda_Angola.pdf
Tamanho:
1.37 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (IHMT)